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The daunting task required of the gut-barrier to prevent luminal pathogens and harmful substances from entering into the
internal milieu and yet promoting digestion and absorption of nutrients requires an exquisite degree of coordination between
the diﬀerent architectural units of this barrier. The complex integration and execution of these functions are superbly carried out
by the intestinal mucosal (IM) surface. Exposed to trillions of luminal microbes, the IM averts threats by signaling to the innate
immune system, through pattern recognition receptors (PRR), to respond to the commensal bacteria by developing tolerance
(hyporesponsiveness) towards them. This system also acts by protecting against pathogens by elaborating and releasing protective
peptides, cytokines, chemokines, and phagocytic cells. The IM is constantly sampling luminal contents and making molecular
adjustments at its frontier. This article describes the topography of the IM and the mechanisms of molecular adjustments that
protect the internal milieu, and also describes the role of the microbiota in achieving this goal.
1.Introduction
The single-cell epithelial layer of the intestinal mucosa
(IM) confronts the largest antigenic microbial challenge of
any other mucosal surface in the human body [1]. The
presence of large microbial communities in the lumen is a
huge problem for the intestinal immune system [2, 3]. In
humans, extensive in utero development of T and B cells
takes place, and after birth there is a rapid and massive
intestinal colonization of antigenic microbes, ultimately
establishing stable microbial communities lasting life-long
for the individual host [1, 4, 5].
The molecular mechanisms that are involved in shaping
and selecting a stable microbiota for diﬀerent individuals
are areas of considerable research interest [6, 7]. There is
evidence emerging that the microbiota modulates a series
of processes that result in maturation, diﬀerentiation, and
proliferation of the IM at both cellular and molecular levels
[3,5,8].Throughamolecularchainofevents,themicrobiota
provides a major drive for the maturation of the innate
a n da d a p t i v ei m m u n es y s t e m s .I th a sap r o f o u n de ﬀect
on the intestinal barrier and on distant organs. In this
review,wepresentmolecularmicrobial-mucosalinteractions
by providing a summary of the diﬀerent strata of the IM,
beginning with the microbiota as the outermost layer, and
describe how diﬀerent layers of the IM form a physical and
immune barrier inﬂuenced by the microbiota [2, 4, 5, 8]. In
this overview, we also describe how microbiota modulates
innate and adaptive immunities.
2. Microbial-MucosalInteractions
Through a process of “cross talk” with the mucosal immune
system, the microbiota negotiates mutual growth, survival,
and inﬂammatory control of the intestinal ecosystem [9,
10]. The IM is equipped with trans-membrane or intra-
cytoplasmic receptors, referred to as pattern recognition
receptors (PRRs) that are deﬁned by their ability to speciﬁ-
cally recognize and bind distinctive microbial macromolecu-
lar ligands (Figure 1). These ligands referred to as microbial-
associatedmolecularpatterns(MAMPs)includelipopolysac-
charide (LPS-a component of gram-negative bacteria), ﬂag-
ellin, peptidoglycans, and formylated peptides [3, 11–14]
(Table 1). The transmembrane PRRs include the family2 Journal of Biomedicine and Biotechnology
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Figure 1: Commensal microbiota, or pathogens, at the mucosal surface create signals, called microbial-associated molecular patterns
(MAMPs), to stimulate pattern recognition receptors (PRRs) including toll-like receptors (TLRs), formylated peptide receptors (FPRs),
or nucleotide-binding oligomerization domain-like receptors (NODs). Subsequent signaling consists of an intricate and inter-relational
pathway, which determines the signaling output based on the initial perception of the triggering organism. Output can be a protective
response to commensal microbiota, an inﬂammatory response to pathogenic organisms, or triggers for apoptosis.
of Toll-like receptors (TLRs), that sample the extracellular
and endosomal compartments, and the intracellular NOD
(Nucleotide-bindingoligomerizationdomain)-likereceptors
(NLRs) that confront and protect the cytoplasmic com-
partment [11–14]. This microbial-mucosal intersignaling
cultivates immune tolerance (hyporesponsiveness) resulting
in the development of a stable core microbiota. Establishing
a core microbiota of diverse and native commensal species
is critical and advantageous to the host as it provides
competition to the pathogenic microbes [9, 15]. This
process prevents pathogens from forming a niche for their
persistence and proliferation [16]. In response to viral com-
ponents,signalingbyTLRsresultsinexpressionofInterferon
1 (IFN1). For fungal components, C-type lectin receptors
s e r v ea sP R R s[ 13]. On the surface of neutrophils, trans-
membrane receptors belonging to the family of formylated
peptide receptors (FPRs) are present as high aﬃnity PRRs
for MAMPs [17]. Upon exposure to MAMPs, signals from
FPRs activate neutrophil transduction pathways to gener-
ate reduced NADPH (nicotinamide adenine dinucleotide
phosphate) oxide (NOX)-dependent reactive oxygen species
and promote phagocytic motility [17]. Recently, several
neutrophil FPRs have been characterized in intestinal epithe-
lial cells (IECs), suggesting that these epithelial receptors
may mediate microbial monitoring in the gut in a manner
analogous to their traditional functions in phagocytes [18].
Disruption in the ligand process of PRRs with MAMPs has
been linked with inﬂammatory intestinal diseases [3]. One
such example is Crohn’s disease, in which mutant forms of
NLR NOD2 have been identiﬁed [3, 19, 20].
2.1. Regulatory Pathways. In the IM, activation of PRRs
initiates regulatory pathways such as nuclear factor κB
(NFκB)/Rel pathways, mitogen-activated protein kinase
(MAPK), and caspase-dependent signaling cascades [14, 19–
21] (Figure 1). The transcriptional response of the IM to
microorganisms can be diﬀerent. Many PRR ligands are
expressedbycommensalbacteriayettheIMdoesnotactivate
an inﬂammatory response to these bacteria. Conversely,
some commensal bacteria exert protective eﬀects by atten-
uating proinﬂammatory responses induced by pathogenic
bacteria. Inﬂammatory or apoptotic responses to pathogenic
bacteria, or stress signals, are controlled by NFκBa n d
caspase-dependent signaling [3, 21–23]. Most commensal
organismslimitthesignalingofNFκBbyinhibitingepithelial
proteosome function, inhibiting degradation of the IκB
(the counter regulatory factor to NFκB), or by exporting
the NFκB subunit p65 out of the nucleus through a per-
oxisome proliferator-activated receptor (PPAR)γ-dependent
pathway. Induction of transforming growth factor-β (TGF-
β) and MMP3K pathways has also been implicated in
anti-inﬂammatory and antiapoptotic eﬀects mediated by
commensals [3, 24–28]. The TLRs can also initiate proapop-
totic signaling. The bacterial lipoprotein-TLR2 interactions
activate the caspase-8 pathway of apoptosis via the myeloid
diﬀerentiation primary-response gene 88 (Myd88) and by
subsequent recruitment of fast activated death domain
(FADD) pathways. Recent ﬁndings utilizing puriﬁed ﬂagellin
and ﬂagellate/aﬂagellate bacteria in both in vitro and in
vivo systems have shown that important roles are played
by ﬂagellin in the modulation of apoptotic responses [21].
In response to cellular (IEC) attack by ﬂagellate pathogens,
signal transduction through TLR5 initiates proinﬂamma-
tory transcriptional responses. Macrophages utilize intra-
cellular IL-1β-converting enzyme protease-activator factor
(IPAF)/neuronal apoptosis inhibitory protein (NAIP) 5 to
detect intracytoplasmic ﬂagellin and respond with IL-1
release and/or apoptosis. Thus, this interaction betweenJournal of Biomedicine and Biotechnology 3
Table 1:Patternrecognitionreceptors(PRRs),microbial-associatedmolecularpatterns(MAMPs),andexpressionpatterns(see,[3, 12, 14]).
PRRs Location MAMPs MAMPs
Non Viral Ligands Viral Ligands
TLRs
TLR1 Cell membrane Lipopeptides
TLR2 Cell membrane
Di-/triacyl lipopeptide Virion (HSV)
Peptidoglycan HA (Measles)
Lipoteichoic acid (LTA)
Zymosan
Porins B and H proteins (HCMV)
Lipoarabinomannan
Phospholipomannan ENv (MMTV)
Glucuronoxylomannan
GPI-linked proteins Core, NS3 (HCV)
Virion
TLR3 Endosome membrane dsRNA RNA viruses
LR4 Cell membrane
Lipopolysaccharide (LPS) ENv protein (MMTV)
Mannan
Glucuronoxylomannan F protein (RSV)
HSP
Fibrinogen
TLR5 Cell membrane Flagellin
TLR6 Cell membrane Lipoprotein, LTA, others
TLR7 Endosome membrane Synthetic ssRNA (e.g., imiquimod, resiquimod (R848) Inﬂuenza A, VSV
TLR8 Endosome membrane Synthetic ssRNA (e.g.,imiquimod, resiquimod (R848) HIV
TLR9 Endosome membrane
CpG DNA Unmethylated DNA (HSV 1,2)
Hemozoin MCMV
Adenovirus
Baculovirus (wild type)
TLR10 Cell membrane Unknown
TLR11 Cell membrane Proﬁlin
NLRs
Nod1 Cytoplasmic Gram-negative peptidoglycan
Nod2 Cytoplasmic Gram-negative and positive peptidoglycan
IPAF Cytoplasmic Flagellin Viral RNA
NALP3 Cytoplasmic RNA
FPR Cell membrane Formylated peptides, ?
FPRL 1-2 Cell membrane Formylated peptides, ?
RIG-1 helicase Cytoplasmic
Synthetic dsRNA HCV,
5 -triphosphate Japanese encephalitis
dsRNA RSV, Inﬂuenza A, EBV
C-type lectins Cell membranes Fungal carbohydrates
Abbreviations: dsRNA: double-stranded RNA; EBV: Epstein-Barr virus; ECMV: encephalomyocarditis virus; GPI: glycosylphosphatidylinositol; HA:
hemagglutinin; HCV: hepatitis C virus; HCMV: human cytomegalovirus; HIV: human immunodeﬁciency virus; HSP: heat-shock protein; HSV: herpes
simplex virus; LPS: lipopolysaccharide; MCMV: murine cytomegalovirus; MMTV: mouse mammary tumor virus; RSV: respiratory syncytial virus; ssRNA:
single-stranded RNA; VSV: vesicular stomatitis virus.
TLR5 and ﬂagellin initiates pro-inﬂammatory and pro-
apoptotic pathways. If pro-inﬂammatory signaling is unim-
peded, transcriptional activation of a battery of anti-
apoptotic/cytoprotective genes arrests the apoptotic path-
ways and allows inﬂammation without cell death [21].
Analogous to these events, it has been reported that dur-
ing infection with wild type Salmonella, ﬂagellin-induced
pro-inﬂammatory signaling reduces cellular pro-apoptotic
responses to bacterial eﬀectors, whereas the absence of this
potent pro-inﬂammatory determinant in mutants allows4 Journal of Biomedicine and Biotechnology
unhindered apoptosis. In this case, activation of pro-
inﬂammatory signals protects apoptosis. Thus, the complex
process of inﬂammation is intertwined with the process of
apoptosis [21].
When activated, the interactive mucosal-microbial infor-
mation system relays posttranslational events to the trans-
ducer PRR which in turn transmits the message, through
transcriptional or post-transcriptional processes, to the
eﬀector cell [1, 5, 22–25].
3. Barrier Defense andInnate Immune System
3.1. Microbiota. By adulthood, a vast consortium of micro-
biota are supported in the intestinal lumen, but with current
microbiologic methods, less than 30% of those microbes
are culturable [15, 29]. Despite our lack of understanding
of the true diversity of luminal microbes, new molecular
approaches are allowing census-based culture-independent
inventories of the entire microbiota and deﬁning the micro-
bial taxonomy utilizing genomic technology [11, 30]. The
most common approach to generate DNA sequence data
is to amplify the genes encoding RNA in small ribosomal
subunits (16S rRNA) using primers targeting generally
conserved regions of the gene. Rapid and cost-eﬀective
methods that provide a “ﬁngerprint” of the microbial
diversity in the individual components of the microbota are
then characterized by cloning and DNA sequencing [15, 30–
32].
Animal experiments and comparisons between conven-
tionally raised mice (or rats) with germ-free counterparts
have revealed that a series of anatomic, biochemical, and
physiologic functions are performed by the microbiota that
are crucial for development, maintaining the integrity of
the barrier function, and for the repair of the IM [5]. The
fact that so many morphological intestinal tissue defects
appear in germ-free animals indicates that the development
of the IM is inherently connected to microbial luminal
colonization. For example, in contrast with conventionally
raised mice, the villus capillaries in germ-free mice develop
poorly during weaning and remain poorly developed until
adulthood, indicating a microbial contribution to angiogen-
esis of the villus-core. This was further conﬁrmed when
it was shown that bacterial colonization of germ-free mice
resulted in rapid and dramatic reinduction of angiogenesis
[5, 33]. Electrophysiologic studies indicate that microbial
colonization improves intestinal motility and modulation
of enzyme activity [34]. Several important eﬀects of the
microbiota on the development of the immune system
have been ascertained by selectively colonizing germ-free
animals and then evaluating immune responses that have
not been inﬂuenced by any other microbial molecules
[11, 28, 35]. Germ-free animals show extensive defects in
the development of gut-associated lymphoid tissue (GALT)
and antibody production, fewer and less cellular lymphoid
follicles (Peyer’s patches), a thinner and less cellular lamina
propria, and fewer plasma cells in germinal centers of the
mesenteric lymph nodes compared with animals housed
under conventional conditions [28, 36, 37]. These ﬁndings
indicate that the development of the ultrastructure of the
IM is dependent on luminal bacteria. The microbiota also
inﬂuences the morphology of the IEC. Germ-free mice have
been shown to develop an altered morphology of their
microvilli and a reduced rate of turnover of their IECs
(intestinal restitution) compared to conventionally raised
animals [38]. Furthermore, the mircobiota has been shown
to direct the glycosylation of surface proteins of the IEC [39].
The microbiota also contributes to the development of
intra-epithelial lymphocytes (IEL) as evident by the fact that
numbers of αβ T-cell receptor (TCR)-bearing IELs (αβIELs)
are reduced in germ-free mice compared to conventionally
raised mice and that γδ TCR-bearing IELs (γδIELs) isolated
from conventionally raised mice are cytolytic but not those
isolatedfromgerm-freemice[5,40–45].Theseﬁndingsindi-
catethatthemicrobiotainﬂuencesmaturationandexecution
of several immune functions that beneﬁt the host IM. In
return,afterbirth,changesoccurinthehostIMthatpromote
colonizationofcommensalorganisms.Conventionallyraised
mice begin life by expressing intestinal epithelial glycans
that predominantly have sialic acid as their terminal moiety.
During weaning there is a shift towards terminal fucose
that does not occur in germ-free mice [40]. Fucosylation of
glycans facilitates colonization by commensal species, such
as B. thetaiotaomicron,t h a tu s et e r m i n a lf u c o s ea sa ne n e r g y
source [46]. Thus, the host’s IM encourages colonization
of commensal organisms by shifting its energy source in
their favor so that the commensals can gain control over the
pathogenic species in the competitive intestinal ecosystem.
Once established, the microbiota then shape their niche
in a way that promotes morphological modulation of the
host’s IM in favor of that host [5, 8]. Another example
is that, compared to conventionally raised mice, germ-free
mice never achieve high activity of Angiogenin-4 (Ang4),
a Paneth cell protein with potent bactericidal activity that
plays important role in epithelial cell defense during the
postweaning-period in mice, indicating that induction of
Ang4 in Paneth cells of the IM is regulated by the microbiota
[43].
The microbiota regulates the intestinal innate immune
system by modulating expression of TLRs and NOD/CARD
(caspase recruitment domain) mediated activation of
immunosensory cells through MAMPs [27]. Decreased
cytoprotective factors and decreased enterocyte prolifera-
tion have been observed in TLR-defective mice [47, 48].
Individual members of the microbiota can dampen TLR-
mediatedinﬂammatorysignalsandexertprotectiveeﬀectsby
attenuating pro-inﬂammatory responses [27, 49] (Figure 1).
Several studies have shown how commensals, and those
bacteria with probiotic function, can suppress inﬂammatory
signals [50, 51]. One of the components of regulation of
inﬂammatory signals is by activating IκB, the inhibitory
component of NFκB activation. Manipulation of the NFκB
pathways has revealed both anti-inﬂammatory and pro-
inﬂammatory roles for this transcriptional control pathway,
suggesting temporal patterns in which TLR and NFκB path-
ways are activated in response to distinct microbial signals.
Mice with IEC-speciﬁc knockout genes encoding for Iκκγ
or Iκκβ, the 2 components of the inhibitory κB kinase (Iκκ)Journal of Biomedicine and Biotechnology 5
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Figure 2:Aschematicillustrationoftherecognitionofmicrobialassociatedmolecularpatterns(MAMPs),suchasLPS(lipopolysaccharide),
by pattern recognition receptors (PRRs) on epithelial cells and activation of three (A, B, and C) pathways that induce production of pro-
inﬂammatory cytokines or chemokines. A. Expressed on the cell membrane of most intestinal epithelial cells (IECs), toll-like receptors
(TLRs) are triggered by LPS. Four toll-like interleukin receptor (TIR) adaptors become involved in propagating TLR signaling, including
Myd88 (myeloid diﬀerentiation primary-response gene 88), TIRAP (toll-interleukin-1 receptor domain containing adapter protein), TRAM
(translocating chain-associated membrane protein), and the TRAF (TNF receptor associated factor) protein family. This interaction induces
phosphorylation and activation of TAK1, leading to activation of IKKs. Inactive IKK sequesters NFκB in the cytoplasm and leads to
degradationofIκB,withsubsequentreleaseofNFκBthatinducestranscriptionofpro-inﬂammatorycytokinesandchemokines.B.Invarious
cells, Myd88-dependent signaling is associated with activations of TAK1, also known as MAP kinases. Extracellular signal-regulated kinase
(MEK) is an intermediary of the MAPK pathway. Activated MEK subsequently phosphorylates ERK which translocates to the nucleus where
it activates multiple transcription factors. Cytoplasmic nucleotide-binding oligomerization domain-like (NOD) receptors also recognize
MAMP. The ligand NOD1 recognizes a peptidoglycan, a constituent only of gram-negative bacteria. NOD2 recognizes constituents of both
gram-positive and gram-negative bacteria. NODs transduce signals in the pathway of NFκB and MAP kinases.
complex that activates NFκB, were found to be susceptible to
chemically induced colitis or to spontaneous development of
intestinal inﬂammation, respectively [50–53]. Upon binding
to their respective MAMPs, the TLRs act together with
the Myd88 adapter protein to induce intracellular signaling
events that converge upon the NFκB and MAPK pathways
to regulate the expression of genes that are involved in
commensal-induced fortiﬁcation of the IM and pathogen-
induced inﬂammation (Figures 1 and 2). TLR ligation
triggers recruitment of Myd88 to the receptor complex
through TIR-TIR domain interactions. The death domain of
Myd88 recruits a death-domain containing protein known
as IL-1-R associated protein kinase (IRAK). Activation of
IRAK leads to activation of NFκB, p38 MAPK, and other
regulators of gene expression. These events and expression
of pro-inﬂammatory genes form the basis of innate immune
response. Studies demonstrating loss of Myd88 function
in dendritic cells established that TLR/Myd88-mediated
MAMP recognition activates dendritic cells to produce pro-
inﬂammatory cytokines and promotes T-helper responses
[41, 49] (Figure 2).
In another study, IEC-speciﬁc deletion of ReIA/P65,
which encodes the primary subunit of the NFκBt r a n -
scription factor, increased epithelial cell proliferation and
causedapoptosisandincreasedsusceptibilitytocolitis.These
ﬁndings indicate that NFκB activation through TLRs on
the IM promoted antinﬂammatory responses to microbial
signalsandpromoteinnateimmunity[10–14,16,20,24,27].
Uncontrolled signaling through TLRs can potentially
cause excessive inﬂammation. Intestinal epithelial cells con-
stitutively, or inducibly, express high levels of the TLR
inhibitor Toll-interacting protein (TOLLIP) [11, 21, 26].
Expression of TOLLIP has been shown to correlate with
the in vivo luminal bacterial load and is highest in healthy
colonic mucosa [26]. There are other regulators, including
single immunoglobulin IL-1R-related protein (SIGIRR),
IRAK-M, A20, PPARγ, and NOD2, which exert inhibitory
inﬂuence over inﬂammation. Evidence suggests that similar
to TOLLIP, NOD2 might suppress the inﬂammatory cascade
and mutations of NOD2 that are associated with Crohn’s
disease. These inhibitory molecules are important in main-
taining microbial homeostasis [26, 28, 35, 40].6 Journal of Biomedicine and Biotechnology
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Figure 3: Under normal physiological conditions, mucin secretion occurring at a stable rate (A) with signals from stable (commensal)
microbiota. Mucin secretion is accelerated (B) upon activation by pathogenic organisms. In gram negative bacteria (e.g., Pseudomonas
aeruginosa), both LPS (lipopolyscaccharide) and ﬂagellin signal activation of RAS-MEK1/2-ERK1/2 (reticulo-activating system-pathway—
meiosis-speciﬁc serine/threonine protein kinase-extracellular signal-regulated kinase) pathways. Bound to LPS binding protein (LBP), LPS
uses a toll-like receptor (TLR). Flagellin binds to a glycolipid receptor, Asialo-GM1, which is calcium dependent. Lipoteichoic acid (LTA),
a component of gram positive bacteria, binds to platelet activating factor (PAF) and activates ADAM10 (adhesion and protease domain
molecule) which engages RAS/RAF/MEK/ERK/pp90RSK/NFκB and MUC2 (intestinal mucin) production.
The microbiota also functions as a regulator of nutrient
metabolism, allowing the host to digest many nutrients
that would otherwise be inaccessible to the IM [3, 25–
27, 36]. The complex carbohydrates that would otherwise be
indigestible are degraded into short-chain fatty acids (SCFA)
and monosaccharides by the mircobiota. These SCFA serve
as a source of energy and regulate growth and diﬀerentiation
ofIECs,especiallyinthecolon.Themicrobiotaalsodegrades
mucus glycoproteins and maintains the speciﬁc landscape of
the IM. Germ-free animals exhibit a dramatic enlargement
of the cecum, largely due to accumulation of undegraded
mucus. In addition, the microbiota modiﬁes the diﬀerenti-
ation programs of intestinal epithelial lineages at key points
during their morphogenesis [5].
3.2. Mucin. A coating of mucus on the IM forms the
front line of defense segregating virulent organisms and
protecting against acidic gastric and duodenal secretions
[54, 55] (Figure 3). This mucus gel consists predominantly
of high molecular weight glycoproteins (mucins) imparting
characteristic polymeric, viscoelastic, and protective prop-
erties. Mucins have a high negative surface charge and a
large hydration capacity. This mesh-like mucin gel impedes
diﬀusion of oﬀending macromolecules and yet is able to
perform functions such as lubrication for the passage of
particulate nutrients, maintenance of epithelial hydration,
and facilitation of the exchange of gases and nutrients across
the IM. So far 21 diﬀerent mucin genes have been identiﬁed.
In the intestine, MUC2 is the major mucin produced by
goblet cells of the IM. Recent investigations in mice colon
havedemonstratedthattherearetwomucuslayersofMUC2,
an inner mucus layer that is adherent to epithelial layer and
an overlying loose mucus layer. The inner layer is densely
packed. Itisdevoid of bacteriasuggestingsmallpore size that
physically prevents bacterial penetration [53]. Conversely,
the outer loose layer contains high number of bacteria.
Because the mucin and protein composition of both the
ﬁrm and loose layers are identical, it appears that ﬁrm layer
separates to form loose layers. In small intestine, the same
MUC2isnotadherenttoepitheliallayerbutformsthemucus
gel that is synthesized in goblet cells. Following synthesis in
goblet cells, mucins are packaged in granules, transported
to the cell surface, and secreted into the intestinal lumen.
Mucins can be secretory or membrane-bound [53–55].Journal of Biomedicine and Biotechnology 7
3.2.1. Mucin and Innate Host Defense. Under normal con-
ditions, microbes localize in the mucus, sharing either
“self” signature molecules or pathogen-associated molecular
patterns. These patterns are in turn recognized by TLRs or
other PRRs. Recognition of LPS is achieved through the
combined action of membrane-bound or soluble mucin,
LPS-bindingprotein(LBP),CD14,andTLR4[55](Figure3).
In gram-negative bacteria (e.g., Pseudomonas aerugi-
nosa), both LPS and ﬂagellin play a role in altering mucin
production (Figure 3). The Binding of LPS to LBP and
then to CD14 leads to activation of Ras-MEK1/2-Erk1/2
(reticulo-activating system-pathway—Meiosis-speciﬁc ser-
ine/threonine protein kinase-extra-cellular signal-regulated
kinase) using TLR-4 as a coreceptor. Flagellin, on the other
hand, binds to the surface glycolipid receptor Asialo-GM1.
The activation of mucin transcription through Asialo-GM1
is calcium dependent as seen by an increase in calcium levels
following administration of ﬂagellin. Binding to Asialo-
GM1 leads to ATP release and its subsequent binding to
the cell surface G protein-coupled receptor (GPCR) [55].
This activates phospholipase C and creates a subsequent
increase in intracellular calcium levels. These events ﬁnally
leadtodownstreamactivationoftheSrc(roussarcomavirus-
cytoplasmic protein)-dependent Ras pathway, leading to the
activation of NFκB and mucin transcription (Figure 3).
Through a diﬀerent pathway, the gram-positive bacterial
product lipoteichoic acid (LTA) binds and activates the
platelet-activating factor (PAF) receptor, which is a cell
surface G-protein coupled receptor (Figure 3). This leads
to activation of ADAM10, which then cleaves the trans-
membrane heparin-binding EGF (epidermal growth factor),
which in turn activates the EGF receptor. This leads to
the engagement of the Ras/Raf/MEK/ERK/pp90rsk/NF-κB
pathway and MUC2 (mucin) transcription [54–56].
The defensive ability of mucin lies in its capacity to
entrap microbes. Adhesion to speciﬁc mucin epitopes is
thought to facilitate mucus colonization by commensal
bacteria, thereby providing a number of growth advantages.
Accordingly, intestinal mucin is thought to dictate the
composition of the bacterial community [55] (Figure 3).
3.2.2. Other Goblet Cell Secretions in Innate Host Defense.
In addition to mucin production, goblet cells also produce
two other innate defense molecules: the intestinal trefoil
factor and the resistin-like molecule-β (RELM-β) proteins
[55, 56]. There is evidence that these two innate defense
molecules may stabilize the mucin polymer and/or regulate
mucinsecretion[55].Importantly,thesemoleculesmayneed
a mucin medium to exert their biological functions.
3.2.3. Intestinal Trefoil Factor. This is a small cystein-rich
peptide belonging to the family of trefoil factors (TFF) [57].
In humans 3 TFFs have been identiﬁed; TFF1, TFF2, and
TFF3. Secreted TFFs act on the IM either extracellularly to
augmentbarrierfunctionorintracellularlyintranscriptional
and signaling events. Trefoils seem to protect the epithelium
and heal injured mucosa. With mucosal injury, TFFs are
up-regulated and stimulate epithelial restitution [57]. They
may also play a role in mucus stabilization by interacting
or cross- linking with mucin to aid in the formation of gel.
SinceTFFsmaybecoexpressedwithsecretedmucins,thereis
possiblyasynergisticactioninmucosalprotectionandrepair
between the two since they are coexpressed in both normal
and injured mucosae [55, 57].
3.2.4. Resistin-Like Molecule-β (RELM-β). This is a member
of the resistin-like molecule (RELM) family. RELM- β is
expressed in both the small and large intestine within IECs
and particularly in goblet cells. RELM-β regulates barrier
integrity and susceptibility to inﬂammation. It appears that
although mucin and RELM-β are secreted by goblet cells,
RELM-β c a na l s oa c ta sa ne ﬀective luminal secretagogue
[55, 58–60].
3.3.TightJunction(TJ)Assembly. TheTJassemblyisacluster
of proteins between intestinal epithelial cells forming an
eﬀective barrier between the lumen and lamina propria [61].
In general, there are three types of junctional complexes, the
tight junctions (TJs), adherens junctions (AJs) and desmo-
somes, and gap junctions [61–64]. Of these three, TJs repre-
sent the major barrier within paracellular pathways between
intestinal epithelial cells [61, 64] (Figure 4). The intestinal
TJ-complex-associated proteins consist of intracellular and
surface membrane proteins. The intracellular proteins are:
zona occludens (ZO)-1, ZO-2, and ZO-3, cingulin, 7H6,
symplekin, and ZA-1 [61, 64, 65] .T h em e m b r a n ep r o t e i n s
localized to the TJ are the following: occludin, claudin,
junctional adhesion molecules (JAMs), and the coxsackie
virus and adenovirus receptor (CAR) proteins [61, 62, 64–
68]. Studies suggest that claudin-1 may directly associate
with occludin laterally in the membrane within the same
cell and the combination of these two proteins functioning
togetherperformsthemajor“gatekeeper”orbarrierfunction
of the tight junction [61, 64–69].
Several signaling pathways of the TJ assembly are being
investigated. Studies indicate that regulation of TJ assembly
occurs through phosphatidylinositol 3-kinase (PI3K) [63].
Prostaglandins have been found to stimulate the recovery of
paracellular resistance via a mechanism involving transep-
ithelialosmoticgradientsandPI3K-dependentrestorationof
TJA.OtherpathwaysimplicatetwoRhofamilyGTPases,Rho
and Rac, and light chain-associated myosin protein kinase 20
for regulation of tight junction proteins. The latter has been
implicated as a mechanism for stress and cytokine-induced
increases in TJ permeability [63].
A number of microorganisms have been shown to attack
the intercellular TJ proteins [61]. Enteric pathogens can
disrupt the TJ of IECs through a number of diﬀerent
virulence factors. Disruption of the TJ by enteropathogenic
Escherichia coli (EPEC) has been attributed, in part, to
alteringoccludindistributionfromtheTJintothecytosol.C.
diﬃciletoxins A and B have been shown to disorganize apical
and basal F-actin and cause dissociation of occludin, ZO-1,
and ZO-2 from the lateral TJ membrane [65–68]. Rotavirus
infection of IECs has been shown to increase paracellular
permeability and cause alteration of F-actin. Furthermore, it8 Journal of Biomedicine and Biotechnology
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Figure 4: A model of the protein components of tight (TJ) and adherens junctions (AJ) in a highly polarized epithelial cell. The TJ is
composedoftransmembraneproteins(occludins,claudins,andJAMs)linkedtoanactincytoskeletonviacytoplasmicZO(zonulaoccludens)
proteins. ZO-1 binds to actin. The AJ is composed of the nectin-afadin system and the E-cadherin-catenin system. Nectin’s direct partner,
afadin, binds to several proteins, including ZO proteins. Thus TJs and AJs may be closely associated, forming the apical junctional complex,
which is linked to the actin cytoskeleton network.
has been determined that the NSP4 (nonstructural protein)
of rotavirus reduces transepithelial electrical resistance,
redistributes ﬁlamentous actin, and prevents lateral targeting
of the TJ-associated ZO-1 protein [65–68].
An endogenous protein called “zonulin,” which is func-
tionally and immunologically related to zonula-occludin
toxin from Vibrio cholera, has been found to disassemble
intercellularTJsviainteractionwithcellmembranereceptors
[65–68]. It is speculated that dysregulation of zonulin in
many diseases may involve loss of cell junction integrity.
Serum zonulin is not only up-regulated in celiac disease, but
also in type 1 diabetes and multiple sclerosis, suggesting the
role for a “leaky gut” in the development of autoimmunity
[61].
Despite their complex organization, neither AJs nor TJs
are static structures and they can be rapidly disassembled
and reorganized in response to various extracellular stimuli.
InternalizationofAJsandTJsappearstobeacommonmech-
anism that rapidly down regulates cell to cell adhesion and
allows remodeling of intercellular junctions. Internalization
isalsoinducedbyvariouspathophysiologicstimuliincluding
microbial virulence factors, pro-inﬂammatory cytokines,
and oxidative stress [61, 62, 64, 66–69] .B r e a k d o w ni nt h e
TJA and in the interepithelial barrier associated with intesti-
nal bacteria has been implicated in several diseases including
inﬂammatory bowel disease (IBD), type I diabetes, and
obesity [61, 66]. Recent studies indicate that the modulation
of microbiota by selectively increasing Biﬁdobacterium-spp
improvesbarrierfunctionandfunctionofTJA-proteins[66].
Endotoxemia and low-grade inﬂammation seen in patients
with obesity and type I diabetes is believed to be associated
with dysbiosis, the presence of a pathogenic microbiota [61,
66, 69]. Developing speciﬁc therapeutic strategies to stabilize
the microbiota, such as the use of probiotics and prebiotics
as an adjunct to management of some of these diseases holds
some promise [70].
3.4. Intestinal Epithelial Layer. Composed of a single layer of
cells that is only ∼20μm thick, the intestinal epithelial layer
has evolved strategies to derive maximum nutritional beneﬁt
from luminal contents and maintain a beneﬁcial host-
microbial relationship while keeping the pro-inﬂammatory
potential of the microbiota under control [36]. As an
interfacebetweenthehostandtheenvironment,themucosal
epithelium consists of well organized crypts and villi
supported by microvasculature, as well as lymphatic and
connective tissues of the lamina propria and submucosa
[1, 25, 27] (Figure 5). Other cellular components include
lymphocytes, macrophages, and ﬁbroblasts that perform
special functions to maintain the integrity of the IM [1–
3, 11, 40, 50, 51, 71].
Studies have shown that several immune functions of
IECs are inﬂuenced by the microbiota, including secretions
of cytokines and chemokines and expression of major
histocompatibility complex (MHC) molecules that directly
interact with lymphocytes [1, 2]. The expression and
localization of PRRs (such as TLRs) is also inﬂuenced by
the microbiota [3, 24, 26, 28, 41, 47, 48]. Expression of
several peptides, such as defensins, is defective in germ-
free animals [28]. Microbial colonization of germ-free miceJournal of Biomedicine and Biotechnology 9
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Figure 5: A depiction of the intestinal epithelial barrier. The intestinal epithelial barrier consists of a rapidly renewing epithelial cell
population, derived from stem cells in the bases of intestinal crypts, that diﬀerentiates into other epithelial cell types (Paneth cells, goblet
cells, enteroendocrine cells, enterocytes, intra-epithelial lymphocytes, and M cells). These cells, as they are produced in the crypts, migrate
to the tips of the villi over approximately 3 to 5 days. This process of repair and restitution can be inﬂuenced by cellular signaling pathways
initiated by the intestinal microbiota. (Modiﬁed from Sharma R, Young C, Mshvildadze M, Neu J. Intestinal Microbiota Does It Play a Role
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induces the production of regenerating islet-derived 3γ
(RegIIIγ), a secreted C-type lectin. RegIIIγ is shown to
have antimicrobial activity by binding to peptidoglycans,
suggesting that microbial species actively shape the intestinal
ecosystem [70–72]. In another study, using cocolonization of
germ-free mice with B. thetaiotaomicron (a symbiont) and
B. longum (a probiotic), Sonnenburg et al. showed that B.
longum can increase the diversity of polysaccharides that can
bedegradedbyB.thetaiotaomicron,thus,demonstratingthat
distinct intestinal bacterial species can aﬀect each other’s
function [73].
3.4.1. Enteroendocrine Cells (EEC). More than ten distinct
types of EEC have been identiﬁed in the adult human
[1]. Entero-endocrine cells secrete serotonin, somatostatin,
motilin, cholecystokinin (CCK), gastric inhibitory peptide
(GIP), neurotensin, vasoactive intestinal peptide (VIP), and
enteroglucagon.AsEECsmigratetothevillustipthenumber
of cytoplasmic granules increases but the ability to divide
decreases. Attempts to map the distribution of EECs using
immune-cytochemical techniques in transgenic adult mice
have been made [74]. The microbiota has been shown to
regulate host energy balance and have an impact on obesity.
This eﬀect is mediated through Gpr41, a G protein-coupled
receptor expressed by a subset of EECs in the IM [74].
3.4.2. Paneth Cells. These cells are the only cell lineage
derived from the crypt stem cells that migrate downward
towards the crypt base. Paneth cells produce lysozyme,
phospholipase A2, TNF-α, cryptdins, and guanylin [75]. The
guanylin family of peptides consists of three endogenous
peptides, one of which has a similar primary structure
and biological activity as that of Escherichia coli heat-
stable enterotoxin (STa). The guanylin and STa both activate
intestinal guanylate cyclase-C (GC-C) and elicit 3 –5  cyclic
guanosine monophosphate (cGMP) accumulation in the
intestinal mucosa. The activation of cGMP drives secretion
of ﬂuids into the intestinal lumen [40, 42, 43, 76].
The cryptdins are defensin-like peptides in intestinal
crypts (Figure 5). Cryptdins kill microbes by forming pores
in their limiting membranes [40, 75]. At least 17 isoforms
have been characterized from a cDNA library. Cryptdin 3
(Cr3) has been shown to induce IL-8 secretion in a dose-
dependant manner when applied to a human intestinal cell
line (T84) by activating NF-κB and p38 MAPK in a calcium-
dependent manner, without inﬂux of extracellular calcium10 Journal of Biomedicine and Biotechnology
(Ca++). Unlike other known inﬂammatory agonists, signal
transduction by Cr3 occurs slowly, suggesting that selective
cryptdins may amplify their roles in innate immunity by
acting as paracrine agonists to coordinate an inﬂammatory
response with the antimicrobial secretions of Paneth cells
[40, 75]. Because of their ability to kill gram-positive
and gram-negative bacteria, fungi, spirochetes, and some
envelopedviruses,cryptdinsareclassiﬁedasbroad-spectrum
antimicrobial peptides [40, 75, 77–79]. Although it is the
least expressed of the six isoforms, cryptdin-4 is the most
bactericidal. Procryptdins, however, are not bactericidal
and thus require degradation of the pro-region by matrix
metalloproteinase-7 (MMP-7) for activation. In response
to bacterial antigens, Paneth cells release their secretory
granules into the lumen of intestinal crypts [40, 79–81].
Defensins are small cationic polypeptides and are the
predominant antimicrobial proteins present in a large num-
ber of expressed genes [1, 80, 81]. Mammalian defensins
are divided into two main structural groups, α and β.
α-defensins are particularly plentiful in neutrophils and
intestinal paneth cells. The antibacterial activity of defensins
is generally ascribed to their ability to disrupt membrane
integrity and function, which ultimately leads to the lysis
of the microorganism [40]. In addition to exerting direct
antimicrobial eﬀects, defensins facilitate and amplify innate
and adaptive immune responses, such as activation and de-
granulation of mast cells, cytokine production and secretion,
maturation of dendritic cells, and chemotaxis of immune
cells [81–83].
Integrins are receptors that mediate attachment between
IECs and the tissues surrounding them, which may be
other cells or the extracellular matrix [40, 82, 84, 85].
Integrins also play a role in cell signaling and thereby deﬁne
cellular shape and mobility, and regulate the cell cycle.
Integrins regulate the assembly of adhesive junctions as well
as the activation of various signaling pathways involved
with complex organization of the epithelial-cell matrix in
maintaining the crypt-villus axis [1, 82–84].
3.4.3. Microfold (M) Cells. These cells are restricted to the
dome epithelium overlying the lymphoid follicles of Peyer’s
Patches in the lamina propria and other lymphoid follicles
in the gut [1, 11, 83]. The surface of M cells is characterized
by microfolds and the numerous vesicles contained within.
Thesecellsperformasigniﬁcantroleinsamplingtheluminal
milieu. They also appear to be the avenue of infection for
viral agents (e.g., rotaviruses of the family, reoviridae) [82,
83]. The numerous vesicles appear to facilitate transport of
luminal antigens, macromolecules, and microorganisms to
the underlying lymphoid tissue [83].
4. Barrier Defense andAdaptive
Immune System
Exposed to a vast number of antigens, the IM is protected
by a large immune system [1, 2]. Both lymphoid cells (T
and B cells) and myeloid cells (macrophages, neutrophils,
eosinophils, and mast cells) have a copious presence in the
gut [14, 16] .T h eG A L Th a se v o l v e ds e v e r a lm o d i ﬁ c a t i o n st o
generate a unique local speciﬁc immunity. Such modiﬁca-
tions can be seen in the mechanisms of antigen processing,
innate or acquired immune functions, the presence of M
cells, and the segregation of the GALT from other mucosa
associated lymphoid tissue (MALT) [11, 25, 36, 86, 87].
The mucosal innate immunity has two components,
nonimmune and immune. The non-immune compo-
nents include physico-chemical barriers including digestive
enzymes, mucin, peristalsis, indigenous microbial ﬂora, and
the epithelial barrier with TJs [61] (Figure 6). The immune
components include cellular and soluble elements. Nearly
all classes of cells participate in natural immunity, including
phagocytes, mast cells, IECs, and natural killer T cells (NK-
T) [1, 2, 35]. Based upon the type of signals received from
surface receptors of the IM, these cells phagocytize a microbe
or antigen, secrete substances facilitating removal of the
oﬀending antigen (e.g., cryptidins), and recruit other cell
types to produce pro-inﬂammatory substances (e.g., IL-8
from IECs and interferon-γ [IFN-γ] from NK-T cells) [36,
40]. These cells also remove altered (by injury or infection)
host cells (e.g., granzymes and perforins from NK-cells) or
modify speciﬁc immune responses (e.g., IL-4 from NK-T
cells). Several of these responses are initiated by interactions
between MAMPs and PRRs [40].
The receptors of the innate immune system are expressed
on IECs and antigen presenting cells including monocytes,
macrophages, B-cells, and dendritic-cells (DCs), [1, 85]
(Figure 6). DCs in the lamina propria are specialized to
regulate T cell immunity. Normally traversing through non-
lymphoid tissue in immature form, DCs switch to immune-
stimulatory mode upon encountering inﬂammatory stim-
uli. This process, referred to as maturation, changes the
phenotype and function of DCs, including up-regulation
of costimulatory and adhesion molecules and expression of
distinct chemokine receptors [85, 86, 88, 89].
With respect to adaptive (acquired) immunity, helper
T (Th) cells can be divided into four distinct cell types.
Th1 cells secrete IL-2 and IFN-γ, a proﬁle that supports
the early events of T-cell and B-cell development (sIgG1
production) as well as cell mediated immunity (delayed-
type hypersensitivity) [14, 34, 87, 88, 90–93]. Th2 cells,
which predominantly secrete IL-4, IL-5, IL-6, IL-10, and IL-
13, have a proﬁle associated with humoral immunity (IgG4
and IgE production). Th3 cells, which predominantly secrete
TGFβ,displayaproﬁleassociatedwithsuppression[88].And
ﬁnally, T-regulatory (T-reg1) cells, which predominantly
secrete IL-10, also have a proﬁle associated with suppression.
Based on these phenotypes, T cells are either considered
eﬀector (Th1, Th2) or regulator (Th3, Treg1) T cells [40,
90]. The cell designated antigen (CD4+) cells which express
CD25, the IL-2 receptor α chain (CD4 + CD25 + cells),
may be particularly important T-regulatory cells capable of
secreting IL-10 and TGF-β. These cytokines are responsible
for diminishing the pro-inﬂammatory process and seem
to prevent autoimmune gastritis and inﬂammatory bowel
disease [86–90]. Through this regulatory mechanism, com-
mensal organisms invoke tolerance (hyporesponsiveness)
to self. Th0 cells exhibit a secretory pattern of cytokinesJournal of Biomedicine and Biotechnology 11
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that includes those associated with Th1 and Th2 patterns,
and also represent newly stimulated T cells. Th0 cells are
driven to become either Th1 cells by IL-12, which stimulates
the transcription factor T-β or Th2 cells by IL-4, which
stimulates the transcription factor GATA-3 [90–92].
Regulatory Treg and Th17 cells are two recently described
s u b s e t sw i t ho p p o s i n ga c t i o n s[ 90]. At a steady state, the
lamina propria maintains a balanced population of cells of
CD4 lineage, TH17 cells, and Treg cells. Th17 cells induce
production of IL-17, a potent inﬂammatory regulator [88–
93]. Production of IL-17 requires the presence of IL-6 and
TGFβ activation, as well as a microbial trigger [93]. It has
been suggested that a balance between Th17 and Treg is
regulated through microbiota that can inﬂuence tolerance
(hypo-responsiveness) or inﬂammatory response [92, 93].
Evidence is accumulating that targeting IL-17 signaling
might prove useful in treating a variety of inﬂammatory
diseases [88–93].
Chemokines present another important family of medi-
ators involved in the immune-inﬂammatory response, acti-
vating chemo-attraction and leucocytes [2]. The receptors
for chemokines (C, CC, CXC, CX3C) are seven membrane
spanning G-protein-linked receptors that are coupled to
cell activation through calcium mobilization and respond
to cytokines of the CXC chemokine family. Interleukin-8
(IL-8 or CXL-8), induced by interferon gamma (Mig or
CXCL9), interferon-inducible protein-10 (IP-10 or CXL10),
and Interferon-inducible T cell chemo-attractant (I-TAC
or CXCL11), belong to the CXC family that are expressed
by enterocytes, presenting another mechanism of immune-
inﬂammatory response by enterocytes [1, 11, 87, 94].
5. Conclusions
External to the IM, the microbiota, mucin, and antibacterial
products (such as defensins and immunoglobulins) protect
the host against pathogens. The layer of epithelial cells
with several components of innate immunity including
PRRs on the surface, NOD2/CARD15 intracellularly, and the
paracelluar space sealed with TJA [40] present a relatively
impermeable brush border. Then, important interactions
take place under the control of the adaptive immune system
in the lamina propria. The dynamic landscape of the IM in
this manner is constantly adjusting to changing conditions12 Journal of Biomedicine and Biotechnology
while providing nutrition and also maintaining eﬃcient
immunity. In this respect, the symbiotic relationship of the
IM with the microbiota is critical [3, 26, 40].
Manipulationsofthemicrobiotatoenhanceitsbeneﬁcial
components that complement the human immune system
with barrier-fortiﬁcation are areas of active research [4,
23, 26, 34]. Disruption in the establishment of a stable
microbiota (dysbiosis) is associated with diseases including
inﬂammatory bowel diseases (IBD), obesity, atopy, and
neonatal necrotizing enterocolitis (NEC) [44, 47, 70, 73].
The immature immune system and frequent exposure to
antibiotics in neonatal intensive care units render premature
infants, who are particularly susceptible to dysbiosis, more
likely to develop NEC. Available conventional therapies for
inﬂammatory intestinal diseases including NEC primarily
target the infectious and inﬂammatory components of the
diseases [3, 61, 73, 84]. The contribution of microbial
communities in maintaining the integrity of the IM and in
facilitating repair emphasizes the rationale for therapeutic
exploitation of commensal organisms. There is evidence
supporting a therapeutic role for probiotic strategies in
treating certain diseases (e.g., IBD, NEC, diarrhea), but
scientiﬁc validations and further research investigating the
eﬃcacy of such strategies without long-term immunolog-
ical complications are warranted, particularly when such
strategies apply to immune-incompetent hosts such as
premature infants or cancer patients [5, 73, 76, 82, 86,
93, 94]. Understanding microbial-mucosal signaling com-
ponents of inﬂammatory pathways and the mechanisms of
how commensal organisms regulate these pathways should
also provide new directions in treating and preventing these
diseases.
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